Every way this can fail — and what’s still standing when it does.
A pitch that only describes success is a pitch you shouldn’t trust. So here is the opposite: the map of every point where this can break, and exactly what value survives each break.
The conclusion is the whole reason the ask is structured as a $1.8M option: the downside branch never returns zero. Every failure mode has a fallback with a known chemistry and a known cost, and even total battery failure leaves Emerson holding five standalone capabilities, two of them with genuine humanitarian value. This page is the receipt for that claim.
A staircase, with no cliff.
Each rung is a known chemistry with a known cost. If the electrolyte you want doesn’t work, you step down. You don’t fall.
What survives each Phase-1 gate failing.
Every Phase-1 gate has an exit ramp, each with capability that remains sellable.
If Chen’s COP+CuFe-PBA+MgCl2 cell won’t reproduce at grid-relevant C-rates, the chemistry thesis ends here. Phase 1 is designed to expose this in the first months. Kill fast.
The cell still works; the electrolyte spec narrows. Cost rises modestly; the purification path complicates but stays inside known chemistry. The commercial framing shifts from “we deleted the industry’s hardest step” to “we’re the second lab to reproduce Chen at pilot scale.” Still a strong first-mover position.
If Emerson’s DeltaV+ICP polish step can’t reach battery grade at scale, the cell ships on imported Nedmag salt (a mature commercial supply). The purification skid becomes a pharma / drinking-water product, a different market with lower purity requirements and a real buyer network.
If pouch cells at 1 Ah work but 3 MWh skid geometry doesn’t (current distribution, edge effects, electrode-stack mechanics), that is a Phase-2 discovery on Phase-2 capital, with no Phase-1 loss. The known unknowns are named explicitly in the Storage Landscape section under “What We Have Not Yet Proven.”
Total battery failure at any gate still leaves Emerson holding five capabilities.
The worst case (Gate 1 fails, chemistry ends) still returns a portfolio of sellable process, instrument, and data capabilities. Two of them are good-for-the-world businesses on their own merits.
Pharma / food / drinking-water remineralization. Global-health product. Nedmag’s existing market.
Cu / B / Li / K / Ba / Sr recovery. Domestic critical-minerals + circular economy.
Turn hypersaline discharge into mineral products. May end up larger than the cell.
Sellable to every battery chemistry (LFP, sodium-ion, whatever wins). De-risks Emerson vs the “wrong chemistry” question entirely.
Rosemount / Micro Motion proof-point into mining, potash, and desalination markets Emerson already serves.
This page is the literal evidence behind the ask.
The Financial Outlook on the proposal prices the option at under 1% of the ~$200M clears-Gate-1 revenue floor. That floor doesn’t assume the battery succeeds commercially, but about three-quarters of it is battery hardware, so it does assume the chemistry clears Gate 1. If the chemistry fails outright, the floor is the five non-battery capabilities, in the tens of millions. The gates below that, the ones this page walks, are what backstop the worst case with things a CFO can underwrite instead of hope for.
Judge the ask on this page rather than on the ceiling. Fund the floor; hope for the tiers above it.
The bounded-downside case is not a reason to be complacent about the science. The mixed-valent bet is real, the reproduction of Chen 2026 is genuinely load-bearing, and the fallback ladder rises in cost at every rung. This page’s job is to show that even the worst outcomes have real floors. It does nothing to soften how much we want the best outcome.
Phase 1’s job is to give the science its fairest chance to succeed. This page is what makes it safe to try.